Regeneron Reports $3.605 Billion Revenue in Q1 2026, 19% Increase Year-Over-Year

Regeneron Pharmaceuticals, Inc. reported a total revenue of $3.605 billion for the first quarter of 2026, marking a 19% increase from $3.029 billion in the same period of 2025. The company's net income for the quarter was $727.2 million, down from $808.7 million year-over-year, resulting in diluted earnings per share of $6.75 compared to $7.27 in the prior year. The increase in revenue was primarily driven by a rise in collaboration revenue, which reached $1.900 billion, up from $1.531 billion in the previous year, while net product sales also saw a modest increase to $1.535 billion from $1.416 billion.

Significant changes in Regeneron's financial performance included a notable decline in net product sales of EYLEA, which fell to $941.5 million from $1.042 billion, attributed to competitive pressures and a transition of patients to EYLEA HD. Conversely, sales of Libtayo increased to $438.2 million from $285.1 million, reflecting strong demand for the product. The company also reported a rise in research and development expenses, which totaled $1.544 billion, up from $1.327 billion, as it continues to invest in its pipeline of new therapies.

In terms of strategic developments, Regeneron announced a new collaboration with the U.S. government in April 2026, agreeing to provide certain products at prices benchmarked against other developed countries. This agreement includes provisions for Most-Favored-Nation Pricing and direct purchasing options for patients. Additionally, the company has authorized a new share repurchase program of up to $3 billion, following a previous program that still has $688.2 million available for repurchases.

Operationally, Regeneron reported an average employee headcount of 15,343, an increase from 15,158 in the prior year. The company continues to expand its geographic footprint and product offerings, with recent approvals for EYLEA HD and ongoing clinical trials for various product candidates. The company is also focused on enhancing its manufacturing capabilities, particularly in response to temporary production interruptions at its facility in Limerick, Ireland.

Looking ahead, Regeneron remains optimistic about its growth trajectory, emphasizing its commitment to advancing its pipeline and maintaining strong collaboration relationships. The company anticipates continued revenue growth driven by its innovative product portfolio, although it acknowledges potential challenges from competitive pressures and regulatory environments. The management's forward-looking statements highlight the importance of successful commercialization of its products and the ongoing development of new therapies to sustain long-term profitability.